Early Detection and Curative Treatment of Early-Stage Hepatocellular Carcinoma

2005 ◽  
Vol 3 ◽  
pp. S144-S148 ◽  
Author(s):  
M KUDO
2017 ◽  
Vol 152 (5) ◽  
pp. S1197
Author(s):  
Chiranjeevi Gadiparthi ◽  
Rosann Cholankeril ◽  
Eddie L. Copelin ◽  
Mairin Joseph-Talreja ◽  
Muhammad Ali Khan ◽  
...  

Hepatology ◽  
2017 ◽  
Vol 65 (4) ◽  
pp. 1237-1248 ◽  
Author(s):  
Benjamin Cadier ◽  
Julie Bulsei ◽  
Pierre Nahon ◽  
Olivier Seror ◽  
Alexis Laurent ◽  
...  

Biomedicines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 97
Author(s):  
Xiao Wang ◽  
Keyan Wang ◽  
Cuipeng Qiu ◽  
Bofei Wang ◽  
Xiaojun Zhang ◽  
...  

The aim of this study was to explore the value of autoantibody to GNAS in the early detection of hepatocellular carcinoma (HCC). In a large-scale sample set of 912 participants (228 cases in each of HCC, liver cirrhosis (LC), chronic hepatitis B (CHB), and normal controls (NCs) groups), autoantibody to GNAS was detected with a positive result in 47.8% of HCC patients, which was significantly higher than that in patients with LC (35.1%), CHB (19.7%), and NCs (19.7%). Further analysis showed that the frequency of autoantibody to GNAS started increasing in compensated cirrhosis patients (37.0%) with a jump in decompensated cirrhosis patients (53.2%) and reached a peak in early HCC patients (62.4%). The increasing autoantibody response to GNAS in patients at different stages was closely associated with the progression of chronic liver lesions. The result from 44 human serial sera demonstrated that 5 of 11 (45.5%) HCC patients had elevated autoantibody to GNAS before and/or at diagnosis of HCC. Moreover, 46.1% and 62.4% of high positive rates in alpha-fetoprotein (AFP) negative and early-stage HCC patients can supplement AFP in early detection of HCC. These findings suggest that autoantibody to GNAS could be used as a potential biomarker for the early detection of HCC.


2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Belaynew Taye ◽  
Paul Clark ◽  
Gunter Hartel ◽  
Elizabeth Powell ◽  
Patricia Valery

Abstract Background Culturally and linguistically diverse communities face several challenges to receiving screening and curative treatment of hepatocellular carcinoma (HCC). We reported the predictors of receipt of treatment and survival in a cohort of patients diagnosed with HCC in Southeast Queensland. Methods Data from 1651 HCC patients (147 migrants) followed between January 1, 2007, and December 31, 2016 were analyzed using chi-square statistic to test for the association between socio-economic variables and receipt of treatment. Bayesian Weibull Accelerated Failure Time regression was used to identify predictors of time to death, and we reported time ratios. Results Receipt of surgical resection for HCC was associated with non-metropolitan residence (P=0.02), non-English language (P<0.001), country of origin (P<0.001), and hepatitis B virus etiology (P<0.001). The median survival time after HCC diagnosis was 9.0 months (interquartile range 2.0‒24.0). The strongest predictors of survival were undifferentiated tumor at presentation (time ratio (TR)=0.30, 95% credible interval (CrI) 0.23‒0.39), age ≥70 years (TR = 0.42, 95%CrI 0.34‒0.53), living in a remote area (TR = 0.67, 95%CrI 0.55‒0.80), and presence of ≥ 1 comorbidity (TR = 0.69 95%CrI 0.54‒0.90). Conclusions Improving access to HCC surveillance and uptake of timely curative treatment for persons living in remote areas and having socioeconomic disadvantage may help patients present to clinic with early stage tumor and provide better survival. Key messages Remoteness of residence is associated with late presentation, low rate of receipt of treatment and predicts survival of patients with HCC.


2017 ◽  
Vol 11 (1) ◽  
pp. 142-147 ◽  
Author(s):  
Toru Setsu ◽  
Atsunori Tsuchiya ◽  
Takayuki Watanabe ◽  
Takuro Nagoya ◽  
Satoshi Ikarashi ◽  
...  

Alpha-fetoprotein (AFP)-L3 was originally reported as a hepatocellular carcinoma (HCC)-specific tumor marker, and recent accumulation of evidence has revealed that AFP-L3 frequency predicts the biological malignancy potential of HCC. However, AFP-L3 elevation from undetectable levels after curative treatment could not be discussed due to the difficulties of calculating AFP-L3 concentrations when serum AFP levels were low. Here, as a novel method, we used highly sensitive AFP-L3 frequency to predict HCC recurrence after curative treatment. Our cases illustrate that recognizing elevation of AFP-L3 from undetectable levels led to the early detection of recurrent HCC due to more careful surveillance.


Sign in / Sign up

Export Citation Format

Share Document